A Phase I/II Study of AZD2811 Nanoparticles (NP) As Monotherapy or in Combination in Treatment-Naïve or Relapsed/Refractory AML/MDS Patients Not Eligible for Intensive Induction Therapy

This article has no abstract
Epistemonikos ID: 8cc4bad644c14fc9ec5e49c9cf4f01900c2b4f05
First added on: Feb 11, 2025